TORONTO — Dr Kieran Moore, Chief Medical Officer of Health, issued the following statement providing an update on the province’s progress responding to this year’s respiratory illness season: “Thanks to the ongoing resilience and commitment of Ontarians, we are seeing a decline in respiratory syncytial virus (RSV), flu and COVID activity throughout the province. RSV trends are beginning to stabilize …
Ontario – Oral antiviral Covid pill’s dispensation Paxlovid increased by over 130 per cent since pharmacists were permitted to prescribe the medication to patients since Dec. 12. Prior to that a prescription from a doctor or clinical assessment centre was required to access the treatment. It works best when taken within five days of start of symptoms. Patients take two …
Ottawa – When COVID-19 first emerged, the Government of Canada and the research community quickly stepped up to develop testing approaches, public health measures, and new vaccines to protect Canadians from the health challenges of the COVID-19 pandemic. The Government of Canada is also investing in safe and effective COVID-19 therapeutics, including antiviral medications. In response to the pressing need …
NEW YORK- Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its COVID-19 oral treatment, PAXLOVIDTM (nirmatrelvir [PF-07321332] tablets and ritonavir tablets). The investment will expand the production of active pharmaceutical ingredient (API) and registered starting materials (RSMs) …
Washington – The World Health Organization gave green light to use Pfizer Inc’s oral COVID-19 antiviral treatment in high-risk patients after an analysis of trial data by it showed the therapy dramatically cut the risk of hospitalization. The recommendation comes as thousands of people die of COVID-19 every week, despite a waning global infection rate. Of existing COVID-19 treatments, Pfizer’s PFE.N Paxlovid is by far …
Reuters – Britain will expand access to Pfizer’s oral antiviral Covid-19 treatment to thousands more people by adding it to a trial to assess how best to use the drug in its highly vaccinated population, the health ministry has said. Paxlovid, a combination of Pfizer’s new pill with an older antiviral ritonavir, was made available to thousands of people with …
Ottawa – Health Canada has authorize the use of Pfizer’s COVID-19 antiviral treatment Paxlovid. Pfizer submitted clinical data for the oral medication to treat mild to moderate cases of COVID-19 in adults, on Dec. 1, 2021.
